<p>Union Health Minister Mansukh Mandaviya and Science and Technology Minister Jitendra Singh launched Bharat Biotech's nasal <a href="https://www.deccanherald.com/tag/covid-19" target="_blank">Covid</a> vaccine, iNCOVACC, on the occasion of Republic Day on Thursday.</p>.<p>The world's first made-in-India intranasal vaccine was launched at Mandaviya's residence here. The nasal vaccine -- BBV154 -- had received the Drugs Controller General of India's (DCGI) approval in November for restricted emergency use among adults as a heterologous booster dose.</p>.<p>According to a statement issued by Bharat Biotech earlier, 'iNCOVACC' is priced at Rs 800 for private markets and at Rs 325 for supplies to the government of India and state governments.</p>.<p><strong>Also Read | <a href="https://www.deccanherald.com/national/india-reports-132-new-covid-cases-active-cases-decline-to-1906-1184756.html" target="_blank">India reports 132 new Covid cases, active cases decline to 1,906</a></strong></p>.<p>iNCOVACC is a recombinant replication deficient adenovirus vectored vaccine with a pre-fusion stabilised spike protein. This vaccine candidate was evaluated in phase I, II and III clinical trials with successful results, the Hyderabad-based vaccine maker had said.</p>.<p>Clinical trials were conducted to evaluate iNCOVACC as a primary dose schedule and as a heterologous booster dose for subjects who have previously received two doses of either Covishield or Covaxin.</p>
<p>Union Health Minister Mansukh Mandaviya and Science and Technology Minister Jitendra Singh launched Bharat Biotech's nasal <a href="https://www.deccanherald.com/tag/covid-19" target="_blank">Covid</a> vaccine, iNCOVACC, on the occasion of Republic Day on Thursday.</p>.<p>The world's first made-in-India intranasal vaccine was launched at Mandaviya's residence here. The nasal vaccine -- BBV154 -- had received the Drugs Controller General of India's (DCGI) approval in November for restricted emergency use among adults as a heterologous booster dose.</p>.<p>According to a statement issued by Bharat Biotech earlier, 'iNCOVACC' is priced at Rs 800 for private markets and at Rs 325 for supplies to the government of India and state governments.</p>.<p><strong>Also Read | <a href="https://www.deccanherald.com/national/india-reports-132-new-covid-cases-active-cases-decline-to-1906-1184756.html" target="_blank">India reports 132 new Covid cases, active cases decline to 1,906</a></strong></p>.<p>iNCOVACC is a recombinant replication deficient adenovirus vectored vaccine with a pre-fusion stabilised spike protein. This vaccine candidate was evaluated in phase I, II and III clinical trials with successful results, the Hyderabad-based vaccine maker had said.</p>.<p>Clinical trials were conducted to evaluate iNCOVACC as a primary dose schedule and as a heterologous booster dose for subjects who have previously received two doses of either Covishield or Covaxin.</p>